ENLIVEN THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 1st, 2023 • Enliven Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
ENLIVEN THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 1st, 2023 • Enliven Therapeutics, Inc. • Pharmaceutical preparations • Colorado
This Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Helen Collins (the “Executive”), effective as of February 23, 2023 (the “Effective Date”).
Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter February 23, 2023Letter Agreement • March 1st, 2023 • Enliven Therapeutics, Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the date signed below (the “Effective Date”). The purpose of this Agreement is to confirm the current terms and conditions of your employment with the Company.
Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) EXHIBIT C FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN IMARA INC. and COMPUTERSHARE INC. AND COMPUTERSHARE TRUST COMPANY, N.A., COLLECTIVELY, AS RIGHTS...Contingent Value Rights Agreement • March 1st, 2023 • Enliven Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of February 23, 2023 is entered into by and among Imara Inc. a Delaware corporation (“Public Company”), and Computershare, Inc., a Delaware corporation and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (collectively, the “Rights Agent”).
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement and General Release • March 1st, 2023 • Enliven Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Separation Agreement and General Release (the “Agreement”) is entered into by and between Imara Inc. (referred to throughout this Agreement as “Employer”) and Rahul Ballal (“Employee”). The term “Party” or “Parties” as used herein shall refer to Employer, Employee, or both, as may be appropriate. The Parties are subject to the terms of a certain Amended and Restated Letter Agreement, dated as of September 23, 2019, and amended on November 5, 2021 (collectively, the “Letter Agreement”), and to the terms of the Invention and Non-Disclosure Agreement and the Non-Competition and Non-Solicitation Agreement, each dated May 21, 2018 (together, the “Restrictive Covenant Agreements”).
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement and General Release • March 1st, 2023 • Enliven Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Separation Agreement and General Release (the “Agreement”) is entered into by and between Imara Inc. (referred to throughout this Agreement as “Employer”) and Michael Gray (“Employee”). The term “Party” or “Parties” as used herein shall refer to Employer, Employee, or both, as may be appropriate. The Parties are subject to the terms of a certain Amended and Restated Letter Agreement, dated as of September 23, 2019 and amended on November 5, 2021 (collectively, the “Letter Agreement”) and to the terms of the Employee Confidentiality, Assignment and Noncompetition Agreement, dated as of April 1, 2019 (the “Restrictive Covenant Agreement”).
